Author

E. K. Lendy

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:virus· 1

Frequent Co-Authors

A. D. Mesecar· 1 shared A. K. Chatterjee· 1 shared A. S. Anderson· 1 shared B. Boras· 1 shared B. J. Anson· 1 shared C. Allerton· 1 shared C. Ma· 1 shared C. Steppan· 1 shared

Activity by Year

2020-2020 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperPharmacology & Toxicology

A. D. Mesecar

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Discovery of a Novel Inhibitor of Coronavirus 3CL Protease as a Clinical Candidate for the Potential Treatment of COVID-19

B. Boras, R. M. Jones, B. J. Anson, D. Arenson, L. Aschenbrenner, M. A. Bakowski, N. Beutler, J. Binder, E. Chen, H. Eng, J. Hammond, R. Hoffman, E. P. Kadar, R. Kania, E. Kimoto, , M. E. McGrath

This study identifies PF-00835321 as a potent inhibitor of SARS-CoV-2 3CL protease with in vitro antiviral activity and clinical evaluation potential.

bioRxiv · Sep 12, 2020 · PreprintPharmacology & Toxicology